Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s ...
BioTime, Inc.Peter Garcia, 510-521-3390, ext 367Chief Financial OfficerorJudith Segall, 510-521-3390, ext 301orLifeMap Sciences, Inc.Kenneth Elsner, 781-826-7719COO BioTime, Inc. (NYSE MKT: BTX) and ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial results for the first quarter ...
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D.
One stock that might be an intriguing choice for investors right now is BioTime, Inc. BTX. This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate ...
Resource is expected to help researchers select the most suitable progenitor cell lines. Regenerative medicines firm BioTime has teamed up with XenneX to establish LifeMap Sciences, an intiiative that ...
BioTime (BTX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.09 per share a year ago. These figures ...
BioTime, Inc. (NYSE MKT: BTX) announced that the company has amended its license from the University of Utah to expand the field of use for which BioTime is licensed to produce and market products ...
<0> BioTime, Inc.Judith Segall, 510-521-3390 ext. 301orInvestor Contact:EVC Group, Inc.Gregory Gin, 862-236-0673James Dawson, 646-445-4800Doug Sherk, 415-652-9100 </0> , Inc. (NYSE MKT: BTX) announced ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX), an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results